(Q50938469)

25 March 2018

title

Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab. (English)

1 reference

25 March 2018

0 references

1 reference

Sultan Al Rashidi

1

1 reference

25 March 2018

Abdullah Al Fawaz

series ordinal

2

1 reference

25 March 2018

Dustan Kangave

series ordinal

3

1 reference

25 March 2018

Ahmed M Abu El-Asrar

series ordinal

4

1 reference

25 March 2018

publication date

4 June 2013

1 reference

25 March 2018

Ocular Immunology and Inflammation

published in

1 reference

25 March 2018

volume

21

1 reference

25 March 2018

issue

6

1 reference

25 March 2018

page(s)

468-474

1 reference

25 March 2018

Novel approaches to Behçet's disease

cites work

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.779727

Uveitis in Behçet disease: an analysis of 880 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.779727

Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.779727

CXC chemokine expression profiles in aqueous humor of patients with different clinical entities of endogenous uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.779727

Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.779727

The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet's disease with ocular involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.779727

Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.779727

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.779727

Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.779727

Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.779727

Multicenter study of infliximab for refractory uveoretinitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.779727

Relationship between serum infliximab levels and acute uveitis attacks in patients with Behcet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.779727

Clinical Course before and after Cataract and Glaucoma Surgery under Systemic Infliximab Therapy in Patients with Behçet's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.779727

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.779727

Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.779727

Adalimumab for the treatment of Behçet's disease: experience in 19 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.779727

Clinical experience with adalimumab in the treatment of ocular Behçet disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.779727

Adalimumab for sight-threatening uveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.779727

Effects of infliximab in the treatment of refractory posterior uveitis of Behçet’s disease after withdrawal of infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.779727

10.3109/09273948.2013.779727

21 January 2018

Identifiers

DOI

1 reference

25 March 2018

PubMed ID

23734940

1 reference

25 March 2018